Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DFD05 vs. Active01 in the treatment of common warts

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510

Common Wart

COMPLETED PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891

Cutaneous Common Warts

COMPLETED PHASE3

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372

Common Wart

COMPLETED PHASE3

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028

Common Wart

COMPLETED PHASE2

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

NCT02849262

Condylomata Acuminata (External)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Common Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DFD05 Cream

Group Type EXPERIMENTAL

DFD05 Cream

Intervention Type DRUG

Active01 Cream

Group Type ACTIVE_COMPARATOR

Active01 Cream

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DFD05 Cream

Intervention Type DRUG

Active01 Cream

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects, any gender or race, must be in good general health as determined by the Investigator with a clinical diagnosis of common warts.
2. Subjects must have at least 1 visible, discrete, common wart with at least a 3 mm longitudinal diameter on the hands, feet (excluding soles) and palms (in that order of priority).
3. The warts must have been present for at least the past 12 weeks, but not more than 3 years
4. Subjects must agree to only use the study products and to not use any other wart-removing product (prescription, OTC or occlusion) during the course of the study.
5. Subjects must be free of any systemic or dermatologic disorder, which in the opinion of the Investigator, will interfere with the study results.
6. Female subjects of childbearing potential must agree to use contraception during the study. All women of childbearing potential must have a negative urine pregnancy test at Screening and Baseline and at 4, 8 \& 12 weeks visits.
7. Subjects are physically able to apply study product to all affected areas or can obtain help.

Exclusion Criteria

1. Women who are pregnant or nursing or planning to become pregnant during the study.
2. Subjects who have been treated for warts within the 30 days prior to the Baseline Visit (e.g. salicylic acid, azelaic acid, cryotherapy).
3. Subjects who have participated in a trial involving any investigational product in the 30 days prior to the Baseline Visit.
4. Subjects with chronic or active liver disease, renal impairment, cutaneous or systemic lupus erythematosus, an autoimmune disorder, immunosuppression, or any other disease or medical condition that would interfere with the study or place the subject at unacceptable risk, as determined by the investigator.
5. Subjects on immunosuppressive agents that would impact their immune response e.g. cyclosporine, mycophenolate mofetil, azathioprine, etc.
6. Subjects who use or have used local/systemic steroids or any other immunosuppressive medication within the 30 days prior to the Baseline Visit.
7. Subjects who use or have used systemic or topical retinoids within the 30 days prior to the Baseline Visit.
8. Subjects who are unable to comply with study requirements.
9. Subjects with other skin diseases like molluscum contagiosum that may confound the evaluation of common warts.
10. Subjects who have received treatment for any type of cancer within 5 years of the Baseline Visit, except skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the Baseline Visit.
11. Subjects unable to comply with study requirements

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No